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Abstract
Background: Inflammation may play a significant role in the pathogenesis of depression, although the molecular target for 
the treatment of inflammation-mediated depressive symptoms remains to be elucidated. Recent studies have implicated the 
NLRP3 inflammasome in various psychiatric disorders, including depression. However, the underlying mechanism by which 
NLRP3 inflammasome activation mediates the progression of depressive-like behaviors remains poorly understood.
Methods: We examined whether NLRP3 deficiency influenced depressive-like behaviors and cerebral inflammation following 
systemic administration of lipopolysaccharide in mice. To further assess the contribution of the NLRP3 inflammasome to the 
progression of depression, we evaluated the effects of NLRP3 signaling on levels of indoleamine 2,3-dioxygenase.
Results: Nlrp3-deficient mice exhibited significant attenuation of depressive-like behaviors and cerebral caspase-1 activation in a 
lipopolysaccharide-induced model of depression. Treatment with the antidepressant amitriptyline failed to block NLRP3-dependent 
activation of caspase-1, but inhibited lipopolysaccharide-promoted production of interleukin-1β mRNA via suppressing NF-κB 
signaling in mouse mixed glial cultures. Interestingly, lipopolysaccharide administration produced NLRP3-dependent increases in 
indoleamine 2,3-dioxygenase expression and activity of mouse brain. Furthermore, inflammasome-activating stimulations, but not 
treatment with the inflammasome product interleukin-1β, triggered indoleamine 2,3-dioxygenase mRNA induction in mixed glial cells.
Conclusions: Our data indicate that the NLRP3 inflammasome is significantly implicated in the progression of systemic 
inflammation-induced depression. NLRP3-dependent caspase-1 activation produced significant increases in indoleamine 
2,3-dioxygenase levels, which may play a significant role in lipopolysaccharide-induced depression. Collectively, our findings 
suggest that indoleamine 2,3-dioxygenase is a potential downstream mediator of the NLRP3 inflammasome in inflammation-
mediated depressive-like behaviors.
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Introduction
An inflammasome is a cytoplasmic caspase-1-activating multi-
protein complex that is composed of a sensor protein such as 
NLRP3, an adaptor protein apoptosis-associated speck-like protein 
containing a caspase-recruitment domain, and an effector protein 
procaspase-1 (Schroder and Tschopp, 2010). Inflammasome com-
ponents are assembled in the cytosol of myeloid cells only upon 
the detection of pathogen- or danger signal-derived molecular pat-
terns and intracellular alterations by the sensor protein (Man and 
Kanneganti, 2016). The assembled inflammasome complex then 
leads to the activation of caspase-1, which in turn mediates the 
maturation and secretion of the proinflammatory cytokines inter-
leukin (IL)-1β and IL-18 (Man and Kanneganti, 2016). Activation of 
inflammasome signaling primarily contributes to host protection 
against microbial infection (Yu and Lee, 2016). However, deregu-
lated inflammasome activation has been increasingly implicated 
in the pathogenesis of metabolic or neurodegenerative disorders 
(Henao-Mejia et  al., 2014; Heneka et  al., 2014). Recently, much 
attention has focused on the NLRP3 inflammasome due to its 
potential association with cerebral inflammation-mediated disor-
ders such as Alzheimer’s disease and childhood cerebral adreno-
leukodystrophy (Heneka et al., 2013; Jang et al., 2016).
Major depressive disorder is a neuropsychiatric disorder asso-
ciated with multiple environmental risk factors, including inflam-
mation (Kaufmann et  al., 2017). The pathophysiology of major 
depressive disorder is still poorly understood, but potentially 
involved in diverse biological symptoms such as monoamine 
deficiency, an elevated level of cortisol and corticotrophin-releas-
ing hormone, and increased production of cytokines (Belmaker 
and Agam, 2008). In detail, the production level of proinflam-
matory cytokines is frequently elevated in patients with major 
depression (Dowlati et al., 2010). Additionally, patients undergo-
ing type 1 interferon therapy showed a higher risk for psychiatric 
symptoms such as depression (Kraus et al., 2003), indicating that 
peripheral inflammation is frequently associated with depressive 
disorder. On a mechanistic basis, cytokines produced via periph-
eral inflammation can cross the blood-brain barrier through 
diffusion or some transporters and activate afferent nerves, pos-
sibly contributing to the etiology of psychiatric disorders (Dantzer 
et al., 2008). Psychological or physical stress may also be involved 
in the pathophysiology of depression (McEwen, 2005). Of interest, 
NLRP3 inflammasome may act as a crucial sensor for psychologi-
cal stress to trigger brain inflammation (Iwata et al., 2016).
Recent evidence further suggests that the NLRP3 inflamma-
some is implicated in depressive disorders (Alcocer-Gomez et al., 
2014; Zhang et al., 2015; Xu et al., 2016). For example, one previ-
ous study reported that levels of inflammasome components (e.g., 
NLRP3 and caspase-1) and inflammasome products (e.g., IL-1β) 
were significantly increased in peripheral blood mononuclear 
cells (PBMC) or serum samples from patients with major depres-
sive disorder (Alcocer-Gomez et al., 2014). Furthermore, selective 
inhibition of caspase-1 by VX-765 or YVAD significantly attenu-
ates depressive-like behaviors triggered by diverse stimulations 
such as lipopolysaccharide (LPS) injection, chronic mild stress, 
and estrogen deficiency (Zhang et al., 2014, 2015; Xu et al., 2016). 
Caspase-1-deficient mice also exhibit a significant reduction 
in stress-induced depressive-like behaviors (Wong et al., 2016). 
Moreover, stress-induced depressive phenotypes were markedly 
attenuated in Nlrp3-deficient mice (Alcocer-Gomez et al., 2016), 
indicating that NLRP3-mediated inflammasome signaling plays 
a significant role in the progression of depressive-like behaviors. 
Supporting these findings, antidepressant amitriptyline treat-
ment significantly reduced mRNA expression levels of inflam-
masome components, including NLRP3 and caspase-1, in PBMCs 
of patients with major depressive disorder (Alcocer-Gomez et al., 
2014). Another study further demonstrated that amitriptyline sup-
presses the release of IL-1β in LPS-stimulated rat mixed glial cells 
(Obuchowicz et al., 2006). However, the underlying mechanism by 
which the NLRP3 inflammasome mediates depressive-like behav-
iors remains poorly understood. Therefore, in the present study, 
we examined the role of the NLRP3 inflammasome in LPS-induced 
depressive-like symptoms using Nlrp3-deficient mice.
Our findings indicate that indoleamine 2,3-dioxygenase (IDO) 
acts as a potent downstream mediator of the NLRP3 inflamma-
some. IDO catabolizes tryptophan (Trp) into kynurenine (Kyn), 
which lead to attenuation of neurotransmitter serotonin pro-
duction (Moore et al., 2000; Walker et al., 2014). Previous studies 
intriguingly revealed that inflammatory contexts, including LPS-
administered mice and interferon α-treated patients, promote 
the increase in the brain level or activity of IDO (Andre et al., 
2008; Walker et al., 2014; Fischer et al., 2015). In addition to the 
monoaminergic system, IDO-mediated pathways may lead to 
the production of neurotoxic molecules such as quinolinic acid, 
which activates N-methyl-D-aspartate (NMDA) receptor and 
stimulates glutamate release, both of which have been impli-
cated in depression (Walker et al., 2013, 2014; Miller and Raison, 
2016). Given the possible involvement of IDO in the inflamma-
tion-related depressive disorder, we here present novel findings 
that NLRP3 inflammasome mediates the upregulation of IDO.
Materials and Methods
Mice
C57BL/6 and Nlrp3-/- (C57BL/6 background) mice were obtained 
from Jackson Laboratory and bred at Yonsei University 
College of Medicine. All mice were maintained under specific 
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pathogen-free conditions. Seven- to 10-week-old male mice 
were used for all experiments. Protocols for the animal experi-
ments were approved by the Institutional Ethical Committee, 
Yonsei University College of Medicine (2014-0257). All experi-
ments were performed in accordance with the approved guide-
lines of the Institutional Ethical Committee.
Reagents and Antibodies
LPS, ATP, nigericin, amitriptyiline, glibenclamide, and poly dA:dT 
were purchased from Sigma-Aldrich. Z-VAD-fmk was obtained 
from Bachem. Recombinant mouse interferon-γ (IFN-γ) and 
IL-1β were purchased from PeproTech. Recombinant mouse 
IL-18 was purchased from Sino Biological. Anti-mouse caspase-1 
(1:2000) and anti-NLRP3 (1:1000) antibodies were obtained 
from Adipogen. Anti-mouse IL-1β (1:4000) antibody was from 
R&D Systems. Anti-IL-18 antibody (1:500) was obtained from 
Santa Cruz. Anti-phospho-IκB and IκB antibodies (1:1000) were 
obtained from Cell Signaling.
Depression-Related Behavioral Tests
To induce depressive-like symptoms, mice were i.p. injected with 
LPS (1.8 mg/kg) or PBS as a control. Systemic administration of 
LPS causes not only depression-like behavior but also results 
in cytokine-induced sickness behavior (Dantzer et al., 2008). To 
minimize the experimental bias caused by sickness response, we 
performed all the behavioral tests after 24 hours post LPS admin-
istration (Remus and Dantzer, 2016). At 24 hours post injection, 
body weights of mice were measured, and the tail suspension 
test (TST) was then performed as previously described (Steru 
et al., 1985; O’Connor et al., 2009). Briefly, mice were suspended 
by the tail with adhesive tape such that their heads remained 
approximately 10 cm above the floor for 6 min, and the proce-
dure was recorded using a video camera. Time spent immo-
bile during the last 4 min was counted. At 28 h post-injection, 
the forced swim test (FST) was then conducted as previously 
described (Porsolt et al., 1977; O’Connor et al., 2009). Briefly, mice 
were individually placed in a cylinder (diameter: 15 cm; height: 
22 cm) containing 15 cm of tap water maintained at 24°C. Then, 
mice were video recorded for 6 minutes, and the time spent 
immobile was analyzed during the last 4 minutes. Immobility 
was defined as no motion or movement, with the exception of 
the minimal movement required to float. The sucrose prefer-
ence test was conducted as follows: Mice were group-housed 
(2 mice/cage) and habituated to drink 1.5% sucrose solution for 
48 hours. After adaptation, mice were deprived of water for 24 
hours. Mice were then injected with LPS or PBS and were given 
both normal water and 1.5% sucrose solution. Consumption of 
normal and sucrose-containing water was measured per cage 
at 24 hours post-LPS/PBS injection, and the sucrose preference 
was calculated as follows: (consumed sucrose water)/(consumed 
sucrose water + normal water) × 100. Sucrose preference was 
evaluated in 5 or 6 cages. To measure locomotor activity in the 
open field, mice were placed individually in an open field arena 
(43.5 × 43.5 × 30.5  cm) and allowed to explore freely for 20 min-
utes. Activity was recorded using a camera mounted above the 
open field arena and analyzed by SMART 2.5 software. The total 
distance traveled was used to represent locomotor activity.
Cell Cultures
Mouse brain mixed glial cells were prepared from the whole 
brains of mouse pups on the first postnatal day as previously 
described (Kim et al., 2013) and cultured in DMEM/F-12 medium 
supplemented with 10% FBS and 100 U/mL penicillin/strepto-
mycin for 2 to 3 weeks. Mouse bone marrow cells were isolated 
from mouse femurs and differentiated into bone marrow-
derived macrophages (BMDMs) with L929-conditioned medium 
(Fernandes-Alnemri et  al., 2010). BMDMs were maintained in 
L929-conditioned DMEM supplemented with 10% FBS and anti-
biotics. Mouse hippocampal HT-22 cell lines were maintained in 
DMEM supplemented with 10% FBS and antibiotics.
Assay of Cerebral Inflammation
After 24 hours post injection, mice were killed by CO2 asphyxi-
ation. To evaluate levels of central nervous system (CNS)-
associated phagocytes, hippocampal slices were isolated from 
mouse brains, suspended in DMEM supplemented with 10% 
FBS, and dissociated to single cells using a Pasteur pipette. 
Cells were then filtrated using a cell strainer, following which 
they were resuspended in PBS containing 10% FBS and stained 
with anti-CD45-BV421 (1:50, BD Biosciences) and anti-CD11b-
PE antibodies (1:50, eBioscience). Cells were then analyzed via 
flow cytometry, and CD45+CD11b+ cells were considered as CNS-
associated phagocytes (Cazareth et  al., 2014). To quantify the 
levels of proinflammatory cytokines in the brain, hippocampal 
slices or whole brain tissues were homogenized using 25 mM 
Tris-Cl (pH 7.5) containing 1% NP-40, 150 mM NaCl, 1% sodium 
deoxycholate, 0.1% SDS, and protease inhibitors. The samples 
were then sonicated and centrifuged. The soluble fractions 
were normalized based on protein concentration using Bradford 
assay and then used to quantify the levels of proinflammatory 
cytokines via ELISA.
Quantification of mRNA Expression
Quantitative real-time PCR was performed to quantify levels of 
mRNA expression in the brain. Briefly, total cellular RNA was 
prepared from mouse brains using a TRIzol reagent (Invitrogen) 
with homogenization and sonication and reverse transcribed 
using PrimeScript RT Master Mix (Takara) in accordance with the 
manufacturer’s instructions. Template DNA was amplified by 
quantitative real-time PCR using SYBR Premix Ex Taq II (Takara). 
The following primers were used: 5′-GGC TAG AAA TCT GCC TGT 
GC-3′ and 5′-AGA GCT CGC AGT AGG GAA CA-3′ (mouse Ido); 5′-
GCC CAT CCT CTG TGA CTC AT-3′ and 5′-AGG CCA CAG GTA TTT 
TGT CG-3′ (mouse Il-1b); 5′-AGT TGC CTT CTT GGG ACT GA-3′ 
and 5′-TCC ACG ATT TCC CAG AGA AC-3′ (mouse Il-6); 5’-ATG 
CTG CTT CGA CAT CTC CT-3’ and 5’-AAC CAA TGC GAG ATC CTG 
AC-3’ (mouse Nlrp3).
Assay of IDO Activity
To determine the IDO activity of mouse brain, the concentra-
tion of kynurenine and tryptophan was measured by high per-
formance liquid chromatography (HPLC) analysis. At 24 hours 
post injection, mouse brain homogenates were prepared in the 
lysis buffer containing 25 mM Tris-Cl (pH 7.5), 1% NP-40, 150 mM 
NaCl, 1% sodium deoxycholate, 0.1% SDS, and protease inhibi-
tors. Homogenates were normalized by Bradford assay and used 
to quantify the level of kynurenine and tryptophan by HPLC-MS/
MS analysis. Liquid-liquid extraction using water-saturated 
ethyl acetate was performed, and aqueous layer was injected 
into HPLC-Tandem mass spectrometry (MS/MS) on phenomenex 
Kinetex C18 column to separate kynurenine and tryptophan in 
selective reaction monitoring mode (kynurenine m/z 209 > 192; 
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tryptophan m/z 205 > 118). To further assess the enzyme activity 
of IDO in the hippocampal homogenates of mouse brain, IDO1 
activity assay kit (BioVision) was used according to the manu-
facturer’s instruction. One unit of IDO1 activity is the amount of 
enzyme that generates 1 μmol of detected N-formylkynurenine 
per minute by oxidation of 1 μmol L-tryptophan at 37°C.
Assay of Inflammasome Activation
To activate NLRP3 inflammasome, cells were primed with LPS 
(0.25 μg/mL) for 3 hours, followed by treatments with ATP (2 mM, 
45 minutes) or nigericin (5 μM, 45 minutes). To stimulate absent in 
melanoma 2 (AIM2) inflammasome, cells were transfected with 
poly dA:dT (1  μg/mL) using a Lipofectamine 2000 (Invitrogen) 
for the indicated times according to the manufacturer’s proto-
col. Inflammasome activation was determined by the detection 
of active caspase-1 p20 and active IL-1β in culture supernatants 
using immunoblots and by quantification of extracellular IL-1β 
using the mouse IL-1β Quantikine ELISA kit (R&D Systems). To 
assess the presence of active caspase-1 in the brain, hippocam-
pal slices were prepared from mouse brains and dissociated into 
single cells as described above. Cells were then stained with 
an active caspase-1-specific FAM-FLICA (ImmunoChemistry 
Technologies) probe in accordance with the manufacturer’s pro-
tocol. FLICA-positive cells were then assayed via flow cytometry.
Immunoblotting
Cells were lysed in 20 mM HEPES (pH 7.5) buffer containing 0.5% 
Nonidet P-40 (NP-40), 50 mM KCl, 150 mM NaCl, 1.5 mM MgCl2, 
1 mM EGTA, and protease inhibitors. Soluble lysates were sub-
jected to SDS-PAGE and then immunoblotted with the appro-
priate antibodies. For some experiments, culture supernatants 
from BMDMs or mixed glial cells were collected after inflamma-
some stimulations, and proteins were precipitated by the addi-
tion of a methanol/chloroform mixture as reported previously, 
following which they were immunoblotted. All blots presented 
in figures are representative images of at least 3 independent 
experiments.
Statistical Analysis
All values were expressed as the mean and SE of individual 
samples. Data were analyzed using 1-way ANOVA followed by 
Dunnett’s posthoc test for comparison of all groups with control 
group or 2-way ANOVA with Bonferroni posthoc test for com-
parison between wild-type and Nlrp3-deficient mice group. The 
level of statistical significance was set at P ≤ .05. Analyses were 
performed with GraphPad Prism.
Results
NLRP3 Deficiency Attenuates LPS-Induced 
Depressive-Like Symptoms
To evaluate the role of the NLRP3 inflammasome in inflamma-
tion-mediated depression, we i.p. injected LPS into wild-type or 
Nlrp3-knockout mice and conducted behavioral tests as sum-
marized in Figure  1A. Consistent with the findings of previ-
ous studies, LPS injection resulted in a significant increase in 
depression-like behaviors in wild-type mice at 24 and 28 hours 
post injection, as assessed via the TST (P < .001; Figure 1B) and 
FST (P < .001; Figure  1C) (O’Connor et  al., 2009; Aguilar-Valles 
et al., 2014). Compared with wild-type mice, Nlrp3-deficient mice 
exhibited a significant reduction in the time spent immobile 
in both behavioral tests following LPS administration (P < .01, 
Figure  1B; P < .001, Figure  1C). However, sucrose preference 
decreased in both mouse groups following LPS administration, 
although this preference was significantly higher in LPS-treated 
Nlrp3-deficient mice than in wild-type mice (P < .05; Figure 1D), 
indicating that inflammation-mediated reductions in sucrose 
preference may be attenuated by deficiencies in NLRP3. On the 
other hand, both groups of mice showed a significant impair-
ment of locomotor activity as measured by the total distance 
traveled via open field test (P < .001, wild-type; P < .001, Nlrp3-
knockout) (Figure  1E). Furthermore, there was no significant 
difference in locomotor activity between wild-type and Nlrp3-
knockout mice following PBS or LPS injection (P > .05). Supporting 
these observations, both wild-type and Nlrp3-knockout mice 
showed a similar loss in the body weight at 24 hours post LPS 
treatment (P < .001) (Figure 1F). These findings collectively dem-
onstrate that systemic inflammation-induced depressive-like 
behaviors were significantly attenuated in Nlrp3-knockout mice.
NLRP3 Deficiency Attenuates LPS-Induced Caspase-1 
Activation in the Brain
To examine whether the observed attenuation in depression-
like behaviors in Nlrp3-deficient mice resulted from reduced 
brain inflammation, we first assessed the population of 
CD45+CD11b+ cells in the hippocampal region of the mouse 
brain. CD45+CD11b+ cells represent CNS-associated phago-
cytes such as neutrophils or monocytes and are the primary 
mediators of LPS-induced cerebral inflammation (Cazareth 
et  al., 2014). Indeed, we observed that LPS administration 
caused a slight but significant increase in the population of 
CNS-associated phagocytes in the hippocampal region of wild-
type mice (P < .05) (Figure  2A-B). However, no such increases 
were observed in Nlrp3-deficient mice (P > .05). We then meas-
ured levels of the proinflammatory cytokine IL-1β, a final 
product of the inflammasome signaling pathway, in mouse 
brain homogenates via ELISA. Systemic administration of LPS 
induced a significant increase in levels of IL-1β in the mouse 
brain homogenates after 6 and 24 hours of administration 
(P < .001, 6 hours; P < .05, 24 hours) (Figure 2C). However, there 
was no significant difference in the level of IL-1β between the 
whole brain homogenates of wild-type and Nlrp3-deficient 
mice following LPS administration (P > .05) (Figure 2D). On the 
other hand, the level of IL-1β was significantly elevated in the 
hippocampal region of wild-type mice (P < .05), but not that of 
Nlrp3-knockout mice (P > .05) after LPS injection (Figure  2E). 
Unlike other proinflammatory cytokines, the production of 
active IL-1β requires unique posttranslational processing of 
inactive precursor pro-IL-1β by active caspase-1 (Black et  al., 
1988). As the quantification of IL-1β by ELISA cannot distinguish 
active IL-1β from immature pro-IL-1β, the detection of active 
caspase-1 is a much more significant indication of inflamma-
some activation. We thus examined the activation of caspase-1 
in the hippocampal region using an active caspase-1-specific 
FLICA probe. Intriguingly, LPS administration caused a marked 
increase in FLICA-positive cells from the hippocampal area of 
wild-type mice (P < .001) (Figure 2F-G). In contrast, the number 
of active caspase-1-containing cells in the hippocampal region 
did not significantly increase in Nlrp3-deficient mice following 
LPS administration (P > .05) (Figure 2F-G). These findings dem-
onstrate that systemic LPS administration promoted robust 
cerebral caspase-1 activation in a NLRP3-dependent manner 
possibly contributing to depression-like behavior.
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Antidepressant Amitriptyline Does Not Inhibit 
NLRP3-Dependent Caspase-1 Activation but 
Suppresses LPS-Triggered IL-1β mRNA Production
To further elucidate the pathophysiological role of NLRP3-
dependent caspase-1 activation in depression, we examined the 
effects of the tricyclic antidepressant amitriptyline on NLRP3 
inflammasome activation. Amitriptyline did not attenuate cas-
pase-1 activation upon stimulation with NLRP3-activating LPS/
ATP and LPS/nigericin treatments in mouse mixed glial cells 
(Figure  3A). Consistent with this observation, amitriptyline 
failed to inhibit the activation of caspase-1 in mouse BMDMs 
stimulated with NLRP3 agonists (Figure 3B). Nevertheless, ami-
triptyline markedly reduced the level of IL-1β in the culture super-
natants of mixed glial cells and BMDMs upon NLRP3-activating 
stimulations as determined by immunoblotting (Figure  3A-B) 
and ELISA (P < .001) (Figure  3C-D). Indeed, amitriptyline pro-
duced a robust inhibition of IL-1β mRNA induction in mixed 
glial cells and BMDMs in response to LPS stimulation (P < .001) 
(Figure  3E-F). This reduction of IL-1β mRNA levels by amitrip-
tyline may explain the observed attenuation in IL-1β secretion 
from mixed glial cultures or BMDMs upon NLRP3 inflamma-
some stimulation. Supporting these data, amitriptyline clearly 
dampened the phosphorylation and degradation of IκB, which 
are typical indications of NF-κB signaling activation, in BMDMs 
upon LPS stimulation (Figure 3G). These data demonstrate that 
the antidepressant amitriptyline may inhibit LPS-triggered IL-1β 
mRNA induction leading to attenuated IL-1β secretion, without 
influencing NLRP3-mediated caspase-1 activation.
NLRP3 Inflammasome Contributes to the Induction 
of IDO
Consistent with the findings of a recent study that utilized a 
chemical stress condition (Alcocer-Gomez et al., 2016), our data 
also indicate that NLRP3 deficiency attenuated depression-like 
symptoms in mice upon systemic LPS administration. However, 
the underlying mechanisms by which NLRP3-mediated inflam-
mation mediates depressive-like behaviors remain poorly 
understood. Given that IDO may be a potent mediator between 
inflammation and depression (Andre et al., 2008; O’Connor et al., 
2009; Miller and Raison, 2016), we assessed levels of Ido mRNA 
expression in the mouse brain. Intriguingly, LPS administra-
tion induced a significant increase in levels of IDO in the brains 
of wild-type mice (P < .01), but not in those of Nlrp3-deficient 
mice (Figure 4A). Systemic administration of LPS also increased 
levels of Nlrp3 mRNA in the brains of wild-type mice (P < .001) 
(Figure  4B). To determine IDO activity in brain, we calculated 
the Kyn/Trp ratio in the brain homogenates via HPLC analysis. 
Consequently, LPS administration led to a significant increase in 
Figure 1. Depression-related behavioral tests in wild-type and Nlrp3-deficient mice upon lipopolysaccharide (LPS) administration. (A) Time schedule for behavioral 
tests of mice injected with PBS or LPS. (B-C) The tail suspension test (TST) (B) and forced swim test (FST) (C) were conducted with PBS- or LPS-administered mice at 24 
hours (B) and 28 hours (C) post injection and analyzed. PBS (n = 11), LPS (n = 13). (D) The sucrose preference test (SPT) was conducted with PBS- or LPS-administered 
mice at 24 hours post administration of PBS (n = 5 cages) or LPS (n = 6 cages). (E) The open field test (OFT) was conducted with PBS- or LPS-administered mice at 24 
hours post injection. PBS (n = 6), LPS (n = 6). (F) Body weights (BW) of mice were measured at 24 hours post administration, and the weight loss was displayed. PBS 
(n = 11), LPS (n = 13). (B-F) Data were analyzed by 2-way ANOVA with Bonferroni posthoc test. Asterisks indicate significant differences. (*P < .05; **P < .01; ***P < .001; n.s., 
not significant).
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Kyn/Trp ratio in brains of wild-type mice (P < .001), while no sig-
nificant change was observed in Nlrp3-deficient mice following 
LPS injection (Figure 4C). Furthermore, IDO1 enzymatic activity 
of brain hippocampal homogenates was significantly increased 
in the LPS-administered wild-type mice (P < .05), but not in the 
Nlrp3-deficient mice (Figure 4D).
To determine whether the NLRP3 inflammasome is involved in 
the induction of Ido, we measured levels of Ido mRNA in mouse 
brain mixed glial cultures. Interferon-γ (IFN-γ) was used as a posi-
tive control to induce Ido mRNA expression (P < .001) (Figure  4E). 
Interestingly, LPS/ATP stimulation produced a significant induc-
tion of Ido mRNA in mixed glial cultures (P < .01, Figure 4E; P < .001, 
Figure 4F), while neither LPS alone nor ATP alone caused the upreg-
ulation of Ido (P > .05) (Figure 4E-F). This LPS/ATP-mediated induc-
tion of Ido was not observed in Nlrp3-deficient mixed glial cells 
(Figure 4G), suggesting that the NLRP3 inflammasome is respon-
sible for the induction of Ido. On the other hand, antidepressant 
amitriptyline showed no inhibition on the LPS/ATP-induced upreg-
ulation of Ido mRNA expression in mixed glial cells (Figure 4H).
Inhibition of Inflammasome/Caspase-1 Suppresses 
the Production of IDO
To further confirm whether NLRP3-mediated caspase-1/inflam-
masome activity is required for Ido induction, we examined 
the effect of zVAD, a pan caspase inhibitor, on the expression 
of Ido mRNA. Consequently, zVAD treatment abolished LPS/
ATP-promoted Ido induction in mouse mixed glial cells (P < .001) 
(Figure  5A). Similarly, treatment with glibenclamide, a chemi-
cal blocker of potassium efflux, also significantly reduced the 
induction of Ido mRNA expression triggered by LPS/ATP stim-
ulation (P < .01) (Figure  5B). Both inhibitors clearly decreased 
inflammasome-mediated caspase-1 activation and IL-1β or 
IL-18 secretion in mixed glial cells (Figure 5C). Indeed, the cas-
pase inhibitor zVAD reduced inflammasome-dependent IL-1β 
secretion (P < .001) but not IL-6 secretion (Figure  5D-E). We 
thus examined the possibility that IL-1β or IL-18 mediates Ido 
induction. Unlike LPS/ATP stimulation, neither IL-1β nor IL-18 
treatment induced the expression of Ido mRNA in mixed glial 
cells (Figure 5F). These data demonstrate that inflammasome-
dependent caspase-1 activation, but not the subsequent secre-
tion of IL-1β or IL-18, is a prerequisite for Ido induction in mixed 
glial cells. Next, we examined whether NLRP3 inflammasome-
activating stimulation influences the expression of Ido in mouse 
hippocampal neuronal HT-22 cells, as Ido induction in neu-
rons may lead to impaired production of serotonin. However, 
neither NLRP3-stimulating LPS/ATP treatment nor treatment 
with inflammasome-mediated proinflammatory cytokines 
induced mRNA expression of Ido in HT-22 cells (Figure 5G), indi-
cating that NLRP3 inflammasome activation may induce IDO 
Figure 2. Brain inflammation in wild-type and Nlrp3-deficient mice upon lipopolysaccharide (LPS) administration. (A-B) Hippocampal regions were isolated from PBS- or 
LPS-administered mice at 24 hours post injection and dissociated into single cell suspensions. Cells were then stained with CD11b- and CD45-specific antibodies and ana-
lyzed via flow cytometry. The relative percentages of CD11b+CD45+ cells are plotted in B (n = 4). (C-D) Levels of IL-1β were quantified by ELISA in the brain homogenates of 
untreated mice and LPS-injected mice after 6 or 24 hours of administration (C, n = 4) and of PBS- or LPS-injected mice after 24 hours of administration (D, n = 8). (E) Levels of 
interleukin (IL)-1β were quantified by ELISA in the hippocampal homogenates of PBS- or LPS-injected mice after 24 hours post injection (n = 4). (F-G) Hippocampal regions 
were dissociated into single cell suspension as in (A). Cells were also stained with anti-CD11b antibody, anti-CD45 antibody, and active caspase-1-specific FLICA reagent 
(carboxyfluorescein-YVAD-FMK), following which they were analyzed via flow cytometry (n = 4). (B-E, G) Data were analyzed by 1-way ANOVA with Dunnett’s posthoc test 
(C) or 2-way ANOVA with Bonferroni posthoc test (B, D, E, G). Asterisks indicate significant differences. (*P < .05; **P < .01; *** P < .001; n.s., not significant).
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expression exclusively in mixed glial cells but not in neurons. Of 
note, the activation of AIM2 inflammasome by poly dA:dT trans-
fection also caused a significant increase in Ido mRNA expres-
sion in mixed glial cells (P < .05, Figure 5H), proposing that other 
inflammasome activation rather than NLRP3 could induce the 
upregulation of IDO. Our data thus highlight that IDO may be a 
downstream mediator of caspase-1/inflammasome pathways in 
the pathophysiology of depression.
Discussion
Accumulating evidence has demonstrated that the NLRP3 
inflammasome is closely implicated in the pathogenesis of 
many chronic inflammatory or metabolic disorders (Wen et al., 
2012; Henao-Mejia et al., 2014). In addition, recent studies have 
also proposed that NLRP3 inflammasome activation may be 
implicated in neuroinflammation, neurodegenerative disorders 
(Heneka et  al., 2013; Jang et  al., 2016; Zhang et  al., 2016), and 
neuropsychiatric disorders such as depression (Alcocer-Gomez 
et al., 2014). Intriguingly, a recent study revealed that NLRP3 defi-
ciency clearly abolishes depressive behaviors in mice subjected 
to immobilization stress (Alcocer-Gomez et al., 2016). Given that 
diverse stress signals including microbial toxins, particulate 
matters, and osmotic stress can stimulate the NLRP3 inflam-
masome (Yu and Lee, 2016), it is highly likely that psychological 
stress, a major cause of depression, activates NLRP3-dependent 
inflammasome signaling (Iwata et al., 2016).
In accordance with this finding, our data here indicate that 
Nlrp3-deficient mice were significantly protected from the 
depressive effects of systemic LPS administration. Previous 
studies showed that LPS administration to mice causes acute 
or long-term depression-like behaviors as well as acute sickness 
behaviors (O’Connor et al., 2009; Lawson et al., 2013a; Zhu et al., 
2017). To minimize the overlap with sickness response, we per-
formed behavioral tests after 24 hours of LPS injection similar 
to experimental designs from previous reports (Dantzer et al., 
2008; Remus and Dantzer, 2016). In our data, both wild-type 
and Nlrp3-deficient mice exhibited a similar reduction in the 
locomotion and weight loss at 24 hours post-LPS administra-
tion. Moreover, there was no significant difference in the basal 
locomotion between these groups, indicating that the differ-
ent locomotion or sickness behavior may not account for the 
attenuated depression-like behaviors of Nlrp3-knockout mice. 
Of interest, we found that active caspase-1-containing cells in 
Figure 3. Effect of amitriptyline on NLRP3 inflammasome activation. (A) Mouse brain mixed glial cells were pretreated with amitriptyline (AT, 20 or 50 μM) for 1 hour, 
then primed with lipopolysaccharide (LPS) (0.25 μg/mL, 3 hours), followed by treatment with ATP (2 mM, 45 minutes) or nigericin (nig, 5 μM, 45 minutes). (B) Mouse bone 
marrow-derived macrophages (BMDMs) were pretreated with amitriptyline (AT, 10 or 50 μM) for 1 hour, then primed with LPS (0.25 μg/mL, 3 h), followed by treatment 
with ATP (2 mM, 45 minutes) or nigericin (nig, 5 μM, 45 minutes). (A-B) Culture supernatants (Sup) or cellular lysates (Lys) were immunoblotted with the indicated 
antibodies. (C-F) Mouse mixed glial cells (C, E) or BMDMs (D, F) were pretreated with amitriptyline (AT, 20 or 50 μM) for 1 hour, then primed with LPS (0.25 μg/mL, 3 
hours), followed by treatment with ATP (2 mM, 45 minutes). (C-D) Culture supernatants were assayed for the quantification of IL-1β via ELISA. (E-F) Cellular lysates were 
assayed for the quantification of IL-1β mRNA via quantitative real-time PCR. (C-F) Data were analyzed by 1-way ANOVA with Dunnett’s posthoc test. Asterisks indicate 
significant differences (n = 5, C; n = 3, D; n = 3, E; n = 4, F; ***P < .001). (G) Mouse BMDMs were pretreated with amitriptyline (AT, 50 μM) for 30 minutes, followed by the 
treatment with LPS (0.5 μg/mL) for the indicated times. Cellular lysates were immunoblotted with the indicated antibodies. Unt: untreated.
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the hippocampus were significantly increased in wild-type but 
not in Nlrp3-knockout mice after LPS administration. These data 
further provide important evidence that NLRP3 inflammasome 
activation in the hippocampus actively occurred in our experi-
mental settings. In this regard, the NLRP3 inflammasome may 
represent a relevant physiological target for the treatment of 
depressive symptoms. Nevertheless, the mechanism underlying 
the contribution of NLRP3 inflammasome activation to depres-
sive-like behaviors remains poorly understood.
Emerging evidence has suggested that IDO acts as a central 
mediator of cytokine-induced depression (O’Connor et al., 2009; 
Walker et al., 2014; Miller and Raison, 2016) and that systemic 
LPS administration induces a manifest upregulation of IDO in 
the hippocampal region (Andre et al., 2008; Walker et al., 2013). 
Moreover, selective inhibition of IDO1 by 1-methyl-tryptophan 
significantly attenuates depressive-like behaviors in mice 
treated with LPS (O’Connor et  al., 2009; Lawson et  al., 2013b). 
Given this context, our data provide novel evidence that brain 
IDO expression and activity is elevated in an NLRP3 inflamma-
some-dependent manner. Furthermore, NLRP3 inflammasome-
activating stimulations remarkably increased the expression 
of Ido in mixed glial cultures. However, this Ido induction was 
not observed following treatment with IL-1β or IL-18, indicating 
that inflammasome-dependent caspase-1 activation is respon-
sible for the upregulation of IDO. Of note, the transfection of 
poly dA:dT increased the mRNA expression of Ido in mixed glial 
cells in our data, suggesting that AIM2 inflammasome could also 
mediate the upregulation of IDO. Further studies are required to 
more fully elucidate the contribution of caspase-1 signaling to 
Ido induction.
Previous studies have revealed that tricyclic antidepres-
sant amitriptyline attenuates Nlrp3 mRNA expression in PBMCs 
and serum IL-1β level in patients with major depressive dis-
order (Alcocer-Gomez et al., 2014; Alcocer-Gomez et al., 2017). 
Furthermore, amitriptyline treatment also inhibits the extracel-
lular release of IL-1β from LPS-triggered mixed glial or micro-
glial cells (Obuchowicz et al., 2006). Thus, we examined whether 
the antidepressant amitriptyline impairs NLRP3-dependent 
caspase-1 activation. However, we observed that amitriptyline 
did not abolish ATP or nigericin-triggered NLRP3-mediated cas-
pase-1 activation in BMDMs and mixed glial cells. Consistent 
with this finding, amitriptyline showed no suppressive effect on 
the induction of IDO in mixed glial cells in response to NLRP3-
activating stimulations. On the other hand, amitriptyline sig-
nificantly reduced LPS-stimulated IL-1β mRNA induction in 
mixed glial cells. Supporting this finding, we found that ami-
triptyline clearly inhibited LPS-induced phosphorylation of IκB, 
a robust indication of NF-κB activation. Our data are consist-
ent with the previous study showing that amitriptyline inhib-
its toll-like receptor 4 signaling (Hutchinson et al., 2010). These 
Figure 4. Effect of NLRP3 inflammasome activation on indoleamine 2,3-dioxygenase (IDO) production. (A-C) After 24 hours of PBS or lipopolysaccharide (LPS) admin-
istration, mouse brain homogenates were prepared and assayed for Ido (A) or Nlrp3 (B) mRNA levels via quantitative real-time PCR (n = 4) or employed for the quanti-
fication of kynurenine (Kyn) and tryptophan (Trp) via HPLC analysis (C) (n = 4). (D) At 24 hours post PBS or LPS injection, mouse brain hippocampal homogenates were 
prepared and assayed for IDO1 enzyme activity. IDO1 specific activity of samples was determined as the amount of produced N-formylkynurenine per minute per mg 
protein and expressed as the relative fold value compared with PBS-injected wild type mice (n = 3). (E) Mouse mixed glial cells were untreated or treated with LPS alone 
(0.5 μg/mL, 5 hours), LPS (0.5 μg/mL, 3 hours) followed by ATP (2 mM, 14 hours), or IFN-γ (20 ng/mL, 14 hours) (n = 4, LPS alone; n = 6). (F) Mouse mixed glial cells were 
untreated or treated with LPS alone (0.25 μg/mL, 3 hours), LPS (0.25 μg/mL, 3 hours) followed by ATP (2 mM, 30 minutes), or ATP alone (2 mM, 30 minutes). (n = 3) (G) Wild-
type or Nlrp3 -/- mice mixed glial cells were treated with LPS alone, LPS followed by ATP, or ATP alone (2 mM, 10 hours) (n = 6). (H) Mouse mixed glial cells were pretreated 
with amitriptyline (AT, 50 μM) for 30 minutes, treated with LPS (0.25 μg/mL, 3 hours), followed by ATP treatment (2 mM, 30 minutes). (n = 3) (E-H) Cellular lysates were 
assayed for the quantification of IDO mRNA via quantitative real-time PCR. Data were analyzed by 1-way ANOVA with Dunnett’s posthoc test (E-F, H) or 2-way ANOVA 
with Bonferroni posthoc test (A-D, G). Asterisks indicate significant differences. (*P < .05; **P < .01; ***P < .001; n.s., not significant). Unt, untreated.
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findings thus provide a molecular explanation for the reduced 
IL-1β production by amitriptyline observed in the previous lit-
erature. Interestingly, a recent paper by Alcocer-Gomez et al. 
(Alcocer-Gomez et al., 2017) suggested that 9 common antide-
pressants, including amitriptyline, decreased Nlrp3 mRNA level 
in the blood mononuclear cells of patients with major depres-
sive disorder, possibly via inducing autophagy. It will be interest-
ing to examine whether other antidepressants such as selective 
serotonin reuptake inhibitors directly inhibit NLRP3-dependent 
caspase-1 activation and the subsequent IDO induction in the 
future study. In conclusion, our present data suggest that the 
NLRP3 inflammasome contributes substantially to inflamma-
tion-mediated depressive disorders via increases in brain IDO 
expression or activity. In terms of the effects on IDO induction, 
selective inhibition of NLRP3 or caspase-1, rather than blocking 
of IL-1R, will be a more effective strategy to attenuate inflamma-
tion-mediated depressive-like symptoms.
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